aGvHD: Looking at a 2-6 month approval (priority review) and if successful launch early next year. Looking at a confirmatory study in high risk adults (targeting 50% of the adult market).
ARDS: Wish to replicate results for younger COVID patients; plus other causes of ARDS such as influenza and bacterial pneumonia.
Ann: MSB Q3 Financial Results and Operational Highlights, page-24
-
- There are more pages in this discussion • 154 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add MSB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
99.0¢ |
Change
0.010(1.02%) |
Mkt cap ! $1.130B | |||
| Open | High | Low | Value | Volume |
| 99.5¢ | $1.02 | 98.5¢ | $5.507M | 5.501M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 9996 | 99.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 99.5¢ | 18069 | 3 |
View Market Depth
| Last trade - 16.10pm 28/06/2024 (20 minute delay) ? |
| MSB (ASX) Chart |